1505 related articles for article (PubMed ID: 30619378)
1. Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment.
Fu C; Jiang A
Front Immunol; 2018; 9():3059. PubMed ID: 30619378
[TBL] [Abstract][Full Text] [Related]
2. β-catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8⁺ T cells.
Liang X; Fu C; Cui W; Ober-Blöbaum JL; Zahner SP; Shrikant PA; Clausen BE; Flavell RA; Mellman I; Jiang A
J Leukoc Biol; 2014 Jan; 95(1):179-90. PubMed ID: 24023259
[TBL] [Abstract][Full Text] [Related]
3. Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer.
Bödder J; Zahan T; van Slooten R; Schreibelt G; de Vries IJM; Flórez-Grau G
Front Immunol; 2020; 11():631713. PubMed ID: 33679726
[TBL] [Abstract][Full Text] [Related]
4. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
5. Genetic vaccines to potentiate the effective CD103+ dendritic cell-mediated cross-priming of antitumor immunity.
Zhang Y; Chen G; Liu Z; Tian S; Zhang J; Carey CD; Murphy KM; Storkus WJ; Falo LD; You Z
J Immunol; 2015 Jun; 194(12):5937-47. PubMed ID: 25972487
[TBL] [Abstract][Full Text] [Related]
6. Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity.
Noubade R; Majri-Morrison S; Tarbell KV
Front Immunol; 2019; 10():1014. PubMed ID: 31143179
[TBL] [Abstract][Full Text] [Related]
7. Type I interferon activates MHC class I-dressed CD11b
Duong E; Fessenden TB; Lutz E; Dinter T; Yim L; Blatt S; Bhutkar A; Wittrup KD; Spranger S
Immunity; 2022 Feb; 55(2):308-323.e9. PubMed ID: 34800368
[TBL] [Abstract][Full Text] [Related]
8. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy.
Sánchez-Paulete AR; Teijeira A; Cueto FJ; Garasa S; Pérez-Gracia JL; Sánchez-Arráez A; Sancho D; Melero I
Ann Oncol; 2017 Dec; 28(suppl_12):xii44-xii55. PubMed ID: 28945841
[TBL] [Abstract][Full Text] [Related]
9. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells.
Cueto FJ; Del Fresno C; Brandi P; Combes AJ; Hernández-García E; Sánchez-Paulete AR; Enamorado M; Bromley CP; Gomez MJ; Conde-Garrosa R; Mañes S; Zelenay S; Melero I; Iborra S; Krummel MF; Sancho D
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33980589
[TBL] [Abstract][Full Text] [Related]
10. Plasmacytoid dendritic cells cross-prime naive CD8 T cells by transferring antigen to conventional dendritic cells through exosomes.
Fu C; Peng P; Loschko J; Feng L; Pham P; Cui W; Lee KP; Krug AB; Jiang A
Proc Natl Acad Sci U S A; 2020 Sep; 117(38):23730-23741. PubMed ID: 32879009
[TBL] [Abstract][Full Text] [Related]
11. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
[TBL] [Abstract][Full Text] [Related]
12. HDAC9 deficiency promotes tumor progression by decreasing the CD8
Ning Y; Ding J; Sun X; Xie Y; Su M; Ma C; Pan J; Chen J; Jiang H; Qi C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554611
[TBL] [Abstract][Full Text] [Related]
13. Tumor-Derived Microvesicles Enhance Cross-Processing Ability of Clinical Grade Dendritic Cells.
Dionisi M; De Archangelis C; Battisti F; Rahimi Koshkaki H; Belleudi F; Zizzari IG; Ruscito I; Albano C; Di Filippo A; Torrisi MR; Benedetti Panici P; Napoletano C; Nuti M; Rughetti A
Front Immunol; 2018; 9():2481. PubMed ID: 30455687
[TBL] [Abstract][Full Text] [Related]
14. Batf3-Dependent Dendritic Cells Promote Optimal CD8 T Cell Responses against Respiratory Poxvirus Infection.
Desai P; Tahiliani V; Abboud G; Stanfield J; Salek-Ardakani S
J Virol; 2018 Aug; 92(16):. PubMed ID: 29875235
[TBL] [Abstract][Full Text] [Related]
15. Intestinal Batf3-dependent dendritic cells are required for optimal antiviral T-cell responses in adult and neonatal mice.
Sun T; Rojas OL; Li C; Ward LA; Philpott DJ; Gommerman JL
Mucosal Immunol; 2017 May; 10(3):775-788. PubMed ID: 27600308
[TBL] [Abstract][Full Text] [Related]
16. Batf3
Ziblat A; Horton BL; Higgs EF; Hatogai K; Martinez A; Shapiro JW; Kim DEC; Zha Y; Sweis RF; Gajewski TF
Cell Rep; 2024 May; 43(5):114141. PubMed ID: 38656869
[TBL] [Abstract][Full Text] [Related]
17. Engineering anti-cancer nanovaccine based on antigen cross-presentation.
Warrier VU; Makandar AI; Garg M; Sethi G; Kant R; Pal JK; Yuba E; Gupta RK
Biosci Rep; 2019 Oct; 39(10):. PubMed ID: 31652460
[TBL] [Abstract][Full Text] [Related]
18. Versican-Derived Matrikines Regulate Batf3-Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer.
Hope C; Emmerich PB; Papadas A; Pagenkopf A; Matkowskyj KA; Van De Hey DR; Payne SN; Clipson L; Callander NS; Hematti P; Miyamoto S; Johnson MG; Deming DA; Asimakopoulos F
J Immunol; 2017 Sep; 199(5):1933-1941. PubMed ID: 28754680
[TBL] [Abstract][Full Text] [Related]
19. Concise review: The heterogenous roles of BATF3 in cancer oncogenesis and dendritic cells and T cells differentiation and function considering the importance of BATF3-dependent dendritic cells.
Dabbaghipour R; Ahmadi E; Entezam M; Farzam OR; Sohrabi S; Jamali S; Sichani AS; Paydar H; Baradaran B
Immunogenetics; 2024 Apr; 76(2):75-91. PubMed ID: 38358555
[TBL] [Abstract][Full Text] [Related]
20. Dendritic Cells and Cancer Immunity.
Gardner A; Ruffell B
Trends Immunol; 2016 Dec; 37(12):855-865. PubMed ID: 27793569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
